Aging and cancer share overlapping characteristics,referred to as meta-hallmarks,which elucidate the convergent,antagonistic,or contradictory relationships between aging and cancer.Likewise,as a key characteristic of ...Aging and cancer share overlapping characteristics,referred to as meta-hallmarks,which elucidate the convergent,antagonistic,or contradictory relationships between aging and cancer.Likewise,as a key characteristic of aging,senescent cells share some meta-hallmarks with tumor cells.These hallmarks include apoptosis resistance,metabolic alterations,secretory phenotypes,epigenetic reprogramming,and immune surveillance,all of which play pivotal roles in both tumorigenesis and senescence.Moreover,senolytic drugs,which are a class of agents selectively designed to eliminate senescent cells,have emerged as promising therapeutic agents in oncology and aging-related diseases.Since the discovery of the first senolytic drug in 2015,a diverse array of such agents has been developed.Notably,most senolytic drugs are repurposed from existing anti-tumor therapies,leveraging their shared mechanisms with senescent cells and tumor cells.Thus,this review examines the similarities between senescent cells and tumor cells,providing a better understanding of the meta-hallmarks.Besides,we categorize existing senolytic drugs based upon meta-hallmarks and elucidate the potential molecular mechanisms underlying their effects.By integrating insights from cancer and senescence research,this work aims to inspire innovative strategies for senolytic drug discovery.展开更多
基金supported in part by grants from National Natural Science Foundation of China(Grant Nos.82403746,82172649,and 82373193)China Postdoctoral Science Foundation(Grant No.2024M762256)+2 种基金the Postdoctoral Research Fund of West China Hospital,Sichuan University(Grant No.2024HXBH088)Natural Science Foundation of Sichuan Province(Grant Nos.2025ZNSFSC1716 and 2024NSFSC0627,China)Postdoctoral Fellowship Program of CPSF(Grant No.GZC20241174,China).
文摘Aging and cancer share overlapping characteristics,referred to as meta-hallmarks,which elucidate the convergent,antagonistic,or contradictory relationships between aging and cancer.Likewise,as a key characteristic of aging,senescent cells share some meta-hallmarks with tumor cells.These hallmarks include apoptosis resistance,metabolic alterations,secretory phenotypes,epigenetic reprogramming,and immune surveillance,all of which play pivotal roles in both tumorigenesis and senescence.Moreover,senolytic drugs,which are a class of agents selectively designed to eliminate senescent cells,have emerged as promising therapeutic agents in oncology and aging-related diseases.Since the discovery of the first senolytic drug in 2015,a diverse array of such agents has been developed.Notably,most senolytic drugs are repurposed from existing anti-tumor therapies,leveraging their shared mechanisms with senescent cells and tumor cells.Thus,this review examines the similarities between senescent cells and tumor cells,providing a better understanding of the meta-hallmarks.Besides,we categorize existing senolytic drugs based upon meta-hallmarks and elucidate the potential molecular mechanisms underlying their effects.By integrating insights from cancer and senescence research,this work aims to inspire innovative strategies for senolytic drug discovery.
